Xpert® vanA/vanB
Rapid VRE screening for active outbreak prevention and control in around 48 minutes
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
10 Tests
Unit price
Product is not available for purchase in your region.
Collection devices
product image
Collection Device (Pack of 50)
Unit price
Product is not available for purchase in your region.
Error adding items to cart. If this error persists, please contact Digital Support

The Need

  • Vancomycin Resistant Enterococci (VRE) are a growing public health threat and pose a risk to patient safety in healthcare facilities1
  • In healthcare settings, colonized patients and environmental contamination contribute to VRE spread1
  • High-risk patients colonized with VRE have 24 times the increased infection risk2
  • Infections caused by VRE are associated with high mortality3
  • VRE has an impact on patient length of stay, and in turn, hospitalization costs3
1 Levitus M. et al. Vancomycin-Resistant Enterococci. StatPearls July 17, 2023. https://www.ncbi.nlm.nih.gov/books/NBK513233/?report=reader#_NBK513233_pubdet. Accessed December 11, 2023
2 Alevizakos M, et al. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2016 Dec;4(1):ofw246.
3 Eichel V,M, et al. Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis. Journal of Hospital Infection 141 (2023) 119e128

The Solution

  • The Xpert vanA/vanB test is a rapid and accurate methodfor detection of VRE colonization among high-risk admissions and for screening during outbreaks of VRE
  • Fast, active screening of high-risk patients to prevent the spread of VRE and better manage colonization in healthcare settings

The Impact

  • The Xpert vanA/vanB test facilitates more efficient infection control surveillance programs:4
    – 93% reduction of turn around time from 70.5h with chromogenic agar culture to 4.6h
    – High negative predictive value allows for better management of non-colonized patients
    – Decreased the number of contact patients thereby preventing VRE transmission
    – 94% reduction in overall cost (€14,302 with culture vs €870)
  • Compared to culture, faster time to result may support more effective patient management: more isolation and transmission risk days saved5
    – 141 saved isolation days and 292 saved transmission risk days
4 Birgand G, et al. Lucet JC. Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs. Antimicrobial Resistant and Infection Control.
2013 Nov ; 2:30.
5 Holzknecht BJ, Hansen DS, Nielsen L, Kailow A, Jarløv JO. Screening for vancomycin-resistant enterococci with Xpert® vanA/vanB: diagnostic accuracy and impact on
infection control decision making. New Microbes New Infect. 2017 Jan 12;16:54-59